SWOT Analysis

Published on: 
, , ,
Pharmaceutical Technology, Pharmaceutical Technology-04-02-2016, Volume 40, Issue 4
Pages: 40

A strengths, weaknesses, opportunities, and threats analysis.

A strengths, weaknesses, opportunities, and threats (SWOT) analysis revealed the following observations.


  • Malta has a mature pharmaceutical industry with an adequate manufacturing base and capacity to produce quality drugs. 

  • It has a pool of productive, proficient graduates, who are flexible and hard working.

  • Facilities are designed in line with EU cGMP requirements and may be inspected and accredited by the local supervising entity, the Malta Medicines Authority.

  • Most of the citizens are English-literate or even multilingual.



  • Malta has a very small internal market.

  • There appears to be a lack of innovation within the Maltese pharmaceutical industry.


  • The Government of Malta funded the BioMalta Life Sciences Park, which offers the potential to blend knowledge of the pharmaceutical industry with the biopharmaceutical and biotechnology industry. 

  • The regulatory framework is good and the country embraces the mutual recognition agreement.

  • Investment tax credits and financial assistance in the form of soft loans, guarantees, and interest subsidies from Malta Enterprise are available.

  • There is a 25% reduction in electricity tariffs for the industry beginning in 2015; the current average kW unit price is €0.15.

  • The country has an encouraging legal, political, and social climate and attractive low corporation tax, which embraces the tax imputation system.

  • The country is a strategic hub and gateway to continental Europe and the Euro-Mediterranean, Middle East, and North Africa (MENA) region, with industrial parks located close to Malta’s main shipment and aviation logistic centers.

  • Sound financial services are available, which enabled the swift rebound from the international economic turmoil.

  • Safe and a good quality lifestyle together with a cultural heritage is second to none.


  • Competition from developing countries is increasing.

  • R&D infrastructure and investment are under-developed.

  • Transport infrastructure and storage facilities for temperature-sensitive drugs are not readily available.

Article Details

Pharmaceutical Technology
Vol. 40, No.4
Page: 40

When referring to this article, please cite it as M. Mercieca et al., “SWOT Analysis," Pharmaceutical Technology 40 (4) 2016.